Zobrazeno 1 - 10
of 129
pro vyhledávání: '"N. Bade"'
Autor:
Emma G. Foster, Brady Sillman, Yutong Liu, Micah Summerlin, Vikas Kumar, Balasrinivasa R. Sajja, Adam R. Cassidy, Benson Edagwa, Howard E. Gendelman, Aditya N. Bade
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
The World Health Organization has recommended dolutegravir (DTG) as a preferred first-line treatment for treatment naive and experienced people living with human immunodeficiency virus type one (PLWHIV). Based on these recommendations 15 million PLWH
Externí odkaz:
https://doaj.org/article/ba6d4ed836814c72aee66959707f131a
Autor:
S. S. Timonova, K. A. Smolova, I. A. Kirik, M. S. Pantyushenko, R. L. Anisimov, R. A. Khamitov, A. A. Piskunov, V. N. Bade
Publikováno v:
Биопрепараты: Профилактика, диагностика, лечение, Vol 22, Iss 3, Pp 279-292 (2022)
Maroteaux—Lamy syndrome (mucopolysaccharidosis type VI) is an orphan genetic disease caused by mutations in the arylsulfatase B gene (ARSB), which encodes the lysosomal enzyme arylsulfatase B (ASB). The relevance of the study lies in the need of a
Externí odkaz:
https://doaj.org/article/0b30e05b6856405db940aee08bf4c2fd
Autor:
S. S. Timonova, K. A. Smolova, D. T. Zaripova, M. S. Pantyushenko, M. A. Koroleva, R. L. Anisimov, R. A. Khamitov, A. A. Piskunov, V. N. Bade
Publikováno v:
Биопрепараты: Профилактика, диагностика, лечение, Vol 22, Iss 1, Pp 80-93 (2022)
Mucopolysaccharidosis type VI (Maroteaux–Lamy syndrome) is an orphan genetic disease caused by deficiency of the lysosomal enzyme arylsulfatase B (ASB). The need to develop a highly productive cell line for the production of recombinant ASB, is beh
Externí odkaz:
https://doaj.org/article/58915adae86c4684bea3a680aa9abe9c
Autor:
Emma G. Foster, Nicholas Y. Palermo, Yutong Liu, Benson Edagwa, Howard E. Gendelman, Aditya N. Bade
Publikováno v:
Frontiers in Toxicology, Vol 5 (2023)
More than fifteen million women with the human immunodeficiency virus type-1 (HIV-1) infection are of childbearing age world-wide. Due to improved and affordable access to antiretroviral therapy (ART), the number of in utero antiretroviral drug (ARV)
Externí odkaz:
https://doaj.org/article/b9159025b308451580c072153a6e3201
Autor:
Denise A. Cobb, Nathan Smith, Suyash Deodhar, Aditya N. Bade, Nagsen Gautam, Bhagya Laxmi Dyavar Shetty, JoEllyn McMillan, Yazen Alnouti, Samuel M. Cohen, Howard E. Gendelman, Benson Edagwa
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Antiretroviral therapy (ART) for the treatment of HIV-1 requires life-long daily adherence to supress viral replication, and nucleoside reverse transcriptase inhibitors that are commonly used in ART have not been converted into long-acting agents. He
Externí odkaz:
https://doaj.org/article/e78ef827a6654617b246aed85af2acee
Autor:
Nagsen Gautam, JoEllyn M. McMillan, Devendra Kumar, Aditya N. Bade, Qiaoyu Pan, Tanmay A. Kulkarni, Wenkuan Li, Brady Sillman, Nathan A. Smith, Bhagya L. Dyavar Shetty, Adam Szlachetka, Benson J. Edagwa, Howard E. Gendelman, Yazen Alnouti
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Here, the authors provide a mechanism for an improved version of a nanoformulated myristoylated prodrug of cabotegravir (CAB), named NM2CAB, and its bioavailability, stability and pharmacokinetics in mice and rats performed in independent academic an
Externí odkaz:
https://doaj.org/article/2bfe8aa999a043d6aa5d494a5ae8099d
Publikováno v:
Pharmaceuticals, Vol 15, Iss 12, p 1533 (2022)
Children born to mothers, with or at risk, of human immunodeficiency virus type-1 (HIV-1) infection are on the rise due to affordable access of antiretroviral therapy (ART) to pregnant women or those of childbearing age. Each year, up to 1.3 million
Externí odkaz:
https://doaj.org/article/0548cd9990514ff49e21e8a05e05461d
Autor:
Prasanta K. Dash, Rafal Kaminski, Ramona Bella, Hang Su, Saumi Mathews, Taha M. Ahooyi, Chen Chen, Pietro Mancuso, Rahsan Sariyer, Pasquale Ferrante, Martina Donadoni, Jake A. Robinson, Brady Sillman, Zhiyi Lin, James R. Hilaire, Mary Banoub, Monalisha Elango, Nagsen Gautam, R. Lee Mosley, Larisa Y. Poluektova, JoEllyn McMillan, Aditya N. Bade, Santhi Gorantla, Ilker K. Sariyer, Tricia H. Burdo, Won-Bin Young, Shohreh Amini, Jennifer Gordon, Jeffrey M. Jacobson, Benson Edagwa, Kamel Khalili, Howard E. Gendelman
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-20 (2019)
Here, the authors show that sequential treatment with long-acting slow-effective release ART and AAV9- based delivery of CRISPR-Cas9 results in undetectable levels of virus and integrated DNA in a subset of humanized HIV-1 infected mice. This proof-o
Externí odkaz:
https://doaj.org/article/ad4b010214414d8c84777d8ae90f684b
Autor:
Brady Sillman, Aditya N. Bade, Prasanta K. Dash, Biju Bhargavan, Ted Kocher, Saumi Mathews, Hang Su, Georgette D. Kanmogne, Larisa Y. Poluektova, Santhi Gorantla, JoEllyn McMillan, Nagsen Gautam, Yazen Alnouti, Benson Edagwa, Howard E. Gendelman
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)
Current ART for treatment of HIV-1 infection requires a strict daily regimen adherence. Herein, the authors report the manufacture and characterization of a nanoformulated dolutegravir prodrug with improved cell and tissue penetration, a remarkable a
Externí odkaz:
https://doaj.org/article/9fe938444e464eaea1e85845549ff241
Autor:
Aditya N. Bade, Benson J Edagwa, Denise A. Cobb, Samuel M. Cohen, JoEllyn M McMillan, Nathan Smith, Nagsen Gautam, Yazen Alnouti, Suyash Deodhar, Bhagya Laxmi Dyavar Shetty, Howard E. Gendelman
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Nature Communications
Nature Communications
Treatment and prevention of human immunodeficiency virus type one (HIV-1) infection was transformed through widespread use of antiretroviral therapy (ART). However, ART has limitations in requiring life-long daily adherence. Such limitations have led
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f70cf01b79f0883888ebe8b886fef1d0
https://doaj.org/article/e78ef827a6654617b246aed85af2acee
https://doaj.org/article/e78ef827a6654617b246aed85af2acee